Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma
Por:
de Llano LP, Naval E, Mejía N and Domínguez-Ortega J
Publicada:
2 ene 2022
Ahead of Print:
1 dic 2021
Resumen:
Introduction Fixed-dose long-acting beta2-agonist (LABA)/inhaled corticosteroid (ICS) combinations and add-on therapies as needed are the mainstay for maintenance therapy in asthma. However, more than 40% of patients have an inadequately controlled disease. The development of triple fixed-dose combinations consisting of long-acting muscarinic antagonist (LAMA)/LABA/ICS has paved the way for a new approach to reach therapeutic goals of an optimal control of symptoms and an effective prevention of future exacerbations. Areas covered A search was conducted on PubMed (MEDLINE), using the MeSH terms [asthma] + [indacaterol] + [glycopyrronium] +[mometasone furoate] + [treatment], until October 2021. Original data from clinical trials, prospective and retrospective studies and reviews were selected. Clinical studies with IND/MF/GLY (Enerzair Breezhaler) are summarized, and its place in current asthma therapy is examined. Expert opinion Triple therapy has been shown to be an effective and safe therapeutic option for asthma patients who remain uncontrolled despite ICS/LABA combination. The recently approved single-inhaler indacaterol/glycopyrronium/mometasone fixed dose combination has demonstrated to significantly reduce exacerbations, improve FEV1, symptoms and quality of life compared to ICS/LABA, including, salmeterol/fluticasone combination. Moreover, once-daily dosing may improve adherence.
Filiaciones:
de Llano LP:
Pneumology Service, Lucus Augusti University Hospital, Eoxi Lugo, Cervo y Monforte, Lugo, Spain
:
Pneumology Service, Hospital Universitario de La Ribera, Alzira, Spain
Mejía N:
Medical Affairs Department, Novartis Farmacéutica, Barcelona, Spain
Domínguez-Ortega J:
Allergy Department, Hospital La Paz Institute for Health Research, Madrid, Spain
Respiratory Disease Network Biomedical Research Centre (CIBERES), Spain
|